Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Автор: | Flora, Sanzida Alam |
---|---|
Інші автори: | Azam, Faruque |
Формат: | Дисертація |
Мова: | English |
Опубліковано: |
Brac University
2024
|
Предмети: | |
Онлайн доступ: | http://hdl.handle.net/10361/23693 |
Схожі ресурси
-
A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
за авторством: Khan, Muidul Hasan
Опубліковано: (2024) -
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
за авторством: Paul, Pulock
Опубліковано: (2024) -
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
за авторством: Rahman, Tasnim
Опубліковано: (2024) -
A review on cyclin-dependent kinase 7 (CDK7) Inhibitors as anticancer agents
за авторством: Sorno, Rubina Haque
Опубліковано: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
за авторством: Hoque, Ismoth Ara
Опубліковано: (2024)